Predictive Oncology Inc. POAI Archives - Page 15 of 19

FridayFeb 21, 2020 11:33 am

QualityStocksNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Announces Another Exemplary Addition to its Board

Predictive Oncology (NASDAQ: POAI), a data and artificial intelligence (“AI”) driven discovery services company that provides predictive models of tumor drug response to improve clinical outcomes for patients, today announced that its Board of Directors has unanimously appointed Dan Handley, M.S., Ph.D., to the Board. According to the update, Dr. Handley serves as a professor and the director of the Clinical and Translational Genome Research Institute of Southern California University of Health Sciences. Dr. Handley previously was the chief scientific officer of the Clinical and Translational Genome Research Institute, a Florida 501(c)3 non-profit corporation. “Predictive Oncology is once again very…

WednesdayFeb 19, 2020 11:41 am

Predictive Oncology Inc. (NASDAQ: POAI) Subsidiary Advances Precision Therapeutics by Learning Cancer Behavior, Improving Outcomes

Predictive Oncology subsidiary TumorGenesis developing faster, less costly and more accurate PDx cancer models that better mimic patient’s tumor TumorGenesis revolutionary technology will provide pharmaceuticals with quicker, more effective drug development while significantly improving patient outcomes POAI to begin sales of TumorGenesis’ innovative culture media in the first half of 2020 TumorGenesis, a flagship subsidiary of Predictive Oncology Inc. (NASDAQ: POAI), has made concrete steps in identifying and separating cancer-related biomarkers, which is likely to speed the development of new and effective therapeutics. TumorGenesis media are specially formulated to help researchers isolate and maintain the unique histological and basic biological…

FridayFeb 14, 2020 2:26 pm

QualityStocksNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Names New Member to Board of Directors

Predictive Oncology (NASDAQ: POAI) recently announced the appointment of Pam Prior, CPA, to the company’s Board of Directors. In addition to holding a seat on the board, Prior will also chair the company’s audit committee. An article further discussing the company reads, “Prior, 57, joins POAI’s Board of Directors with 35 years of experience in accounting, mainly in management as CFO or controller. As the founder and CEO of Priorities Group Inc., a provider of CFO services to small and mid-sized businesses, she has served as a CFO to a number of companies, including Gentris Corp., a private pharmacogenomics company…

WednesdayFeb 05, 2020 11:19 am

QualityStocksNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Launches Innovative Culture Media for Growing Ovarian Tumor Cells in the Lab

Predictive Oncology (NASDAQ: POAI), together with its subsidiary, TumorGenesis, Inc., today announced that it has selected US Biological Corporation of Salem, Massachusetts as the manufacturer and distributor of its innovative culture media for growing ovarian tumor cells. TumorGenesis media are specially formulated to help researchers isolate and maintain the unique histological and basic biological signatures of heterogeneous ovarian cell types while growing them in the laboratory, unlike traditional cell culture media that select for one or two fast growing cell types. “Using these proprietary media our partners have identified 25 cell types from ovarian tumors, which to a large degree…

TuesdayJan 28, 2020 1:19 pm

QualityStocksNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Leverages Unique Competitive Advantage

Predictive Oncology (NASDAQ: POAI), a data and artificial-intelligence- (“AI”) driven, discovery-services company, possesses a unique advantage over its competition in the form of samples and access to historical data on clinical outcomes. This data could enable POAI to produce value to pharmaceutical companies significantly faster than its competitors. An article discussing the company reads, “Specifically, POAI can leverage two unique proprietary assets, from its acquisition of Helomics, which virtually eliminate development risk, a factor that considerably weighs on competitors’ efforts in the precision medicine space. First, Predictive Oncology possesses a clinically validated, tumor-profiling platform built from data derived from actual…

FridayJan 24, 2020 1:48 pm

QualityStocksNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Inks LOI to Acquire Quantitative Medicine

Predictive Oncology (NASDAQ: POAI), a data and artificial-intelligence- (“AI”) driven, discovery-services company, today announced that it has signed a letter of intent (“LOI”) to acquire Quantitative Medicine (“QM”), a biomedical analytics and computational biology company. By combining QM’s CoRE predictive modeling platform with POAI’s tumor profiling proficiency and data, company management believes the acquisition will assist in fast-tracking the commercialization of its AI-driven technology and services. Subject to the negotiation of a definitive agreement and other terms and conditions, the transaction is anticipated to be completed within the first two quarters of 2020. “Our goal is to provide researchers in…

FridayJan 24, 2020 12:43 pm

Predictive Oncology Inc. (NASDAQ: POAI) Appoints New Board Member, Audit Committee Chair

New board member, audit committee chair brings 35 years of accounting experience, mainly in management Prior worked as CFO, controller in several genomics, health companies POAI to leverage Prior’s new insights, guidance in the financial space Predictive Oncology Inc. (NASDAQ: POAI), a leader in the cancer precision-medicine field, announced that Pam Prior, CPA, has been appointed to the company's Board of Directors. In addition to holding a seat on the board, Prior will also chair the company’s audit committee. Prior, 57, joins POAI’s Board of Directors with 35 years of experience in accounting, mainly in management as CFO or controller.…

FridayJan 17, 2020 3:33 pm

QualityStocksNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Aims to Commercialize AI-Driven Predictive Model of Ovarian Cancer in Q1 2020

Predictive Oncology (NASDAQ: POAI), a data and artificial-intelligence- (“AI”) driven, discovery-services company that provides predictive models of tumor drug response to improve clinical outcomes for patients, recently issued an update regarding its groundbreaking CancerQuest 2020 initiative driven by its Helomics subsidiary (http://ibn.fm/gs5Qh). Per the update, the company intends to have its first predictive model of ovarian cancer prepared for initial commercialization in the first quarter of 2020. An article discussing the company reads, “‘We believe that this effort will enhance our understanding of the molecular profiles of women with ovarian cancer by using the power of artificial intelligence to create predictive…

FridayJan 17, 2020 12:41 pm

Predictive Oncology Inc. (NASDAQ: POAI), Leader in Precision Medicine, Committed to Playing Key Role in Decreasing Cancer Deaths

American Cancer Society annual report shows largest single-year drop in cancer deaths ever reported Doctors attribute precision medicine with playing significant role in decline POAI leading player in precision medicine, initiated groundbreaking Cancer Quest 2020 project A new American Cancer Society report bodes well for Predictive Oncology Inc. (NASDAQ: POAI), a company focused on applying artificial intelligence to help equip players in personalized medicine and drug discovery. American Cancer Society’s annual ‘Facts & Figures 2020’ report shows the largest single-year drop in cancer deaths ever reported (http://ibn.fm/1d3lE). The 2.2% drop occurred from 2016 to 2017, the most recent year for which…

MondayJan 13, 2020 12:10 pm

Predictive Oncology Inc.’s (NASDAQ: POAI) Disruptive Platform Overcoming Obstacles in Precision Medicine Industry

The global precision medicine market is estimated to reach $84.6 billion by 2024 Predictive Oncology is bringing cutting-edge technology to cancer research to develop highly customizable assessment methods that improve patient outcomes POAI leverages unique competitive advantage that stems from readily available access to historical data on tumor profiles and their drug responses Precision medicine, an approach that seeks to understand the genetic makeup of a patient’s tumor in order to customize a drug targeting the particular gene type for each patient, offers tremendous potential for the treatment of a number of diseases. Predictive Oncology Inc. (NASDAQ: POAI), a data…

Site Search

Company Search

Tag: Predictive Oncology Inc. POAI